Attentive Therapeutics has two patent families covering methods of use/treatment and composition of a single capsule. IP has issued in the US, Europe, and Canada and additional patents are pending.
The company is partnering prior to further product development. We are interested in working with established pharmaceutical and biotechnology firms to develop and commercialize ATT-377 worldwide.
Please reach out to us to learn about our successfully completed clinical study and next steps with the program.
Please send inquiries to email@example.com